Sen. Markwayne Mullin’s financial dealings take on new importance this week as the Senate is set to consider his nomination ...

To start things off, I understand Vaxart is researching oral vaccines for COVID-19, norovirus, and influenza. Could you give us an overview of each program and where they are in the development ...

You've heard of hardware. But have you heard of "wetware?" The post New Data Centers Will Be Powered by Human Brain Cells ...

Gil Efron to Step Down as CEO in August 2026 for Health Considerations; Will Continue to Lead Corporate Development ...

Detailed price information for Kratos Defense & Security Inc (KTOS-Q) from The Globe and Mail including charting and trades.

Astellas Pharma has agreed to co-develop and co-commercialize Vir Biotechnology’s prostate cancer candidate VIR-5500 through a collaboration that could generate more than $1.7 billion for the San ...

African agricultural technology startups raised less than $170 million in 2025, marking the first time since the sector began tracking invest ...

FRANKFURT, March 10 (Reuters) - The cofounders of BioNTech, Ugur Sahin and Oezlem Tuereci, will leave the COVID-19 vaccine maker by the end of 2026 to set up their own new company, the biotech firm ...

Igor Tsyganskiy is now leading Microsoft Research (MSR) as past president Peter Lee takes the helm of Microsoft Science.

India's HPV vaccine, Cervavac, faces delays for inclusion in immunization programs due to ongoing studies and competition ...

Live updates on markets and the top finance, economics and business stories. Plus the latest on oil prices, the Dow, S&P 500 and Nasdaq.

More early-stage data show the drug, called salanersen, appeared to have positive effects on neurodegeneration and motor function in patients previously treated with Novartis' Zolgensma.